Faut-il surveiller la métaplasie intestinale et la dysplasie dans l’estomac ?

详细信息    查看全文

• 作者：D. Lamarque (1)
  
• 关键词：Estomac ; Lésions précancéreuses ; Atrophie glandulaire ; Métaplasie intestinale ; Surveillance ; Stomach ; Pre ; cancerous lesions ; Glandular atrophy ; Intestinal metaplasia ; Follow ; up
• 刊名：Acta Endoscopica
• 出版年：2012
• 出版时间：October 2012
• 年：2012
• 卷：42
• 期：5
• 页码：257-260
• 全文大小：693KB
• 参考文献：1. Mackenzie M, Spithoff K, Jonker D. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol 2011;18:e202–e209. CrossRef
  2. Belot A, Velten M, Grosclaude P, Bossard N, Launoy G, Remontet L, et al. Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2005. Publications de l’Institut de veille sanitaire 2009, cancer_1980_2005/estimation_cancer_1980_2005.pdf" class="a-plus-plus">http://www.invs.sante.fr/publications/2009/estimation_cancer_1980_2005/estimation_cancer_1980_2005.pdf.
  3. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008;38:259-67. CrossRef
  4. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-9.
  5. Fukao A, Hisamichi S, Ohsato N, Fujino N, Endo N, Iha M. Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes Control 1993;4:17-0. CrossRef
  6. Genta RM. Review article: gastric atrophy and atrophic gastritis-nebulous concepts in search of a definition. Aliment Pharmacol Ther 1998;12(Suppl 1):17-3. CrossRef
  7. Kapadia CR. Gastric atrophy, metaplasia, and dysplasia: a clinical perspective. J Clin Gastroenterol 2003;36:S29–S36; discussion S61–S22. CrossRef
  8. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, et al. / Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-4. CrossRef
  9. Suerbaum S, Michetti P. / Helicobacter pylori infection. N Engl J Med 2002;347:1175-186. CrossRef
  10. de Vries AC, Meijer GA, Looman CW, Casparie MK, Hansen BE, van Grieken NC, et al. Epidemiological trends of pre-malignant gastric lesions; a long-term nationwide study in the Netherlands. Gut 2007 56(12):1665-670. CrossRef
  11. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti- / Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-888. CrossRef
  12. Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom / Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-86.
  13. Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, et al. / Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002;16:1449-456. CrossRef
  14. Zhou L, Sung JJ, Lin S, Jin Z, Ding S, Huang X, et al. A five-year follow-up study on the pathological changes of gastric mucosa after / H. pylori eradication. Chin Med J (Engl) 2003;116:11-4.
  15. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on / Helicobacter pylori eradication. Gut 2004;53:1244-249. CrossRef
  16. Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, et al. / Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004;13:4-0. CrossRef
  17. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. / Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94. CrossRef
  18. Lu B, Chen MT, Fan YH, Liu Y, Meng LN. Effects of / Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J Gastroenterol 2005;11:6518-520.
  19. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can / Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-28.
  20. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long-term follow-up of patients treated for / Helicobacter pylori infection. Gut 2005;54:1536-540. CrossRef
  21. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83. CrossRef
  22. Wang J, Xu L, Shi R, Huang X, Li SW, Huang Z, et al. Gastric atrophy and intestinal metaplasia before and after / Helicobacter pylori eradication: a meta-analysis. Digestion 2011;83:253-60. CrossRef
  23. Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, et al. The benefit of mass eradication of / Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2012 [E-pub ahead of print].
  24. Atkins L, Benedict EB. Correlation of gross gastroscopic findings with gastroscopic biopsy in gastritis. N Engl J Med 1956;254:641-44. CrossRef
  25. Stathopoulos G, Goldberg RD, Blackstone MO. Endoscopic diagnosis of intestinal metaplasia. Gastrointest Endosc 1990;36:544-45. CrossRef
  26. Redeen S, Petersson F, Jonsson KA, Borch K. Relationship of gastroscopic features to histological findings in gastritis and / Helicobacter pylori infection in a general population sample. Endoscopy 2003;35:946-50. CrossRef
  27. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-181. CrossRef
  28. Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;56:631-36. CrossRef
  29. Rugge M, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010;31:1104-111.
  30. Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150-158. CrossRef
  31. Satoh K, Kimura K, Taniguchi Y, Kihira K, Takimoto T, Saifuku K, et al. Biopsy sites suitable for the diagnosis of / Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 1998;93:569-73. CrossRef
  32. El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of / Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 1999;30:72-7. CrossRef
  33. Eriksson NK, Farkkila MA, Voutilainen ME, Arkkila PE. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. Endoscopy 2005;37:532-36. CrossRef
  34. Van Zanten SJ, Dixon MF, Lee A. The gastric transitional zones: neglected links between gastroduodenal pathology and helicobacter ecology. Gastroenterology 1999;116:1217-229. CrossRef
  35. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000;95:1431-438. CrossRef
  36. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to / Helicobacter pylori infection. Helicobacter 2007;12:1-5.
  37. Vannella L, Lahner E, Osborn J, Bordi C, Miglione M, Delle Fave G, et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 2010;31:1042-050.
  38. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74-4. CrossRef
  39. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945-52. CrossRef
  40. Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Megraud F, Xiao SD, et al. / Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005;100:2100-115. CrossRef
  41. Leung WK, Ng EK, Chan WY, Auyeung AC, Chan KF, Lam CC, et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev 2005;14:2982-986. CrossRef
  42. Rokkas T, Sechopoulos P, Pistiolas D, Margantinis G, Koukoulis G. / Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol 2010;22:1128-133. CrossRef
  43. Kato I, Vivas J, Plummer M, Lopez G, Peraza S, Castro D, et al. Environmental factors in / Helicobacter pylori-related gastric precancerous lesions in Venezuela. Cancer Epidemiol Biomarkers Prev 2004;13:468-76.
  44. You WC, Zhang L, Gail MH, Chang YS, Liu WD, Ma JL, et al. Gastric dysplasia and gastric cancer: / Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000;92:1607-612. CrossRef
  45. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, et al. Effect of / Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000;46:615-21. CrossRef
  46. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, et al. Cure of / Helicobacter pylori infection in patients with reflux oesophagitis treated with long-term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004-53:12-0.
  
• 作者单位：D. Lamarque (1)
  
  1. Hépatogastroentérologie, h?pital Ambroise-Paré, 9, avenue Charles-de-Gaulle, F-92104, Boulogne-Billancourt, France
  

文摘

The majority of stomach cancers are the result of preneoplastic lesions that have appeared several years previously. This damage is in the form of atrophy and intestinal metaplasia of the gastric mucosa caused by a prior infection due to Helicobacter pylori. Atrophy to the body of the stomach associated with intestinal metaplasia is an identified cancer risk factor. There is a beneficial effect of eradicating H. pylori seen in the evolution of this preneoplastic damage that has yet to reach the intestinal metaplasia stage. A follow-up every three years is recommended, especially for patients who have extensive or severe damage to the body of the stomach and pyloric antrum, regardless of the localisation. In cases of low grade dysplasia discovered at staging biopsies, annual follow-ups are recommended.